Belatacept 3 Month Post Transplant Conversion Study
Randomized Conversion Of Epstein-Barr Virus (EBV)+ Kidney Transplant Recipients Of Living Or Standard Criteria Donors At Three Months Post Transplantation To Belatacept With MPA Or Belatacept With Low-Dose Tacrolimus (50% Of Dose) Compared To Patients Remaining On Center Specific Standard Therapy Of Tacrolimus And MPA
Sponsor: Bristol-Myers Squibb
A PHASE4 clinical study on EBV and Transplant; Failure, Kidney, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 13 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Mar 2023 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
▶ Show 8 earlier versions
-
Sep 2022 — Dec 2022 [monthly]
Completed PHASE4
-
Oct 2021 — Sep 2022 [monthly]
Completed PHASE4
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Nov 2019 — Jan 2021 [monthly]
Recruiting PHASE4
-
Oct 2018 — Nov 2019 [monthly]
Recruiting PHASE4
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Lorenzo Gallon
For direct contact, visit the study record on ClinicalTrials.gov .